Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of ...
Tempest Therapeutics: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...
Tempest receives FDA study may proceed for Phase 3 trial of amezalpat
Tempest Therapeutics (TPST) announced that the company received a “Study May Proceed” letter from the U.S. Food and Drug ...